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a  b  s  t  r  a  c  t
Cell-based  therapies  have  the  potential  to contribute  to  global  healthcare,  whereby  the  use  of  living  cells
and  tissues  can  be  used  as medicinal  therapies.  Despite  this  potential,  many  challenges  remain  before  the
full value  of  this  emerging  ﬁeld  can  be  realized.  The  characterization  of  input  material  for  cell-based  ther-
apy bioprocesses  from  multiple  donors  is necessary  to  identify  and  understand  the  potential  implications
of  input  variation  on  process  development.  In  this  work,  we have  characterized  bone  marrow  derived
human  mesenchymal  stem  cells  (BM-hMSCs)  from  multiple  donors  and  discussed  the  implications  of
the  measurable  input  variation  on the  development  of  autologous  and  allogeneic  cell-based  therapy
manufacturing  processes.  The  range  of  cumulative  population  doublings  across  the  ﬁve  BM-hMSC  lines
over 30  days  of culture  was  5.93,  with  an  18.2%  range  in  colony  forming  efﬁciency  at  the  end  of  the
culture  process  and  a 55.1%  difference  in  the production  of  interleukin-6  between  these  cell lines. It has
been  demonstrated  that  this  variation  results  in a range  in the  process  time  between  these  donor  hMSC
lines  for  a hypothetical  product  of  over  13  days,  creating  potential  batch  timing  issues when  manufac-
turing  products  from  multiple  patients.  All  BM-hMSC  donor  lines  demonstrated  conformity  to  the  ISCT
criteria  but  showed  a difference  in  cell  morphology.  Metabolite  analysis  showed  that  hMSCs  from  the
−1 −1different  donors  have  a  range  in  glucose  consumption  of  26.98  pmol  cell day , Lactate  production  of
29.45  pmol  cell−1 day−1 and  ammonium  production  of 1.35 pmol  cell−1 day−1, demonstrating  the  extent
of  donor  variability  throughout  the  expansion  process.  Measuring  informative  product  attributes  during
process  development  will  facilitate  progress  towards  consistent  manufacturing  processes,  a  critical  step
in the translation  cell-based  therapies.
© 2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Introduction
Regenerative medicine is an expanding ﬁeld, which includes
he use of living cells and tissues as medicinal therapies to treat
urrently unmet clinical need. Cell-based therapies, a platform
echnology, form a signiﬁcant part of this ﬁeld with many treat-
Abbreviations: BM-hMSC, bone marrow derived human mesenchymal stem
ells; MNC, mononuclear cells; FBS, fetal bovine serum; DMSO, dimethylsulphox-
de; CFU-f, colony forming unit ﬁbroblast; QC, quality control; QA, quality assurance;
TR, short tandem repeat; CQA, critical-to-quality attributes; IL-6, interleukin 6; IDO,
ndoleamine 2,3-dioxygenase; MoA, mechanism of action; PAT, process analytical
echnology.
∗ Corresponding author.
E-mail address: c.j.hewitt@aston.ac.uk (C.J. Hewitt).
ttp://dx.doi.org/10.1016/j.bej.2015.06.018
369-703X/© 2015 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
ments for diseases such as cancer, diabetes and stroke currently
progressing through clinical development [1]. Human mesenchy-
mal  stem cells (hMSCs) are a leading candidate for many of these
clinical indications due to their relative ease of isolation, potential
for ex vivo expansion and their ability to secrete a range of trophic
factors which can initiate the regeneration of many tissues. For the
majority of these clinical indications, however, the in vitro expan-
sion of cells is required in order to deliver an effective therapeutic
dose [2]. The intention of this expansion step is to manufacture
a sufﬁcient number of cells to deliver therapeutic beneﬁt without
having a detrimental impact on the quality of the cell. Cell-based
therapies therefore represent a step change from current biophar-
maceutical production, where the product of interest is usually a
protein, not the cell itself. This introduces a range of additional chal-
lenges for the ﬁeld, not least of all how a cell-therapy bioprocess can
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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e developed to consistently manufacture products from multiple
onors.
Autologous cell-based therapies, where the cell donor and
ecipient is the same individual, are patient speciﬁc and their
anufacture must be scaled-out to ensure that patient mate-
ial is segregated and cross-contamination of material is avoided.
cale-out of autologous therapies will likely necessitate multiple
anufacturing facilities, creating the need for local automation
nd the demonstration of comparability between these sites [3,4].
he main advantage of autologous cell-based therapies is the lack
f immune rejection associated with donor transplant material,
liminating the need for immunosuppressive medication, which
ould add signiﬁcant cost to the treatment. Autologous ther-
pies may  also beneﬁt from the development of point-of-care
evices, where functional closed devices can be used to manu-
acture cell-based therapies at the bedside. These typically involve
he isolation and enrichment of cells directly from the patient and
re returned on-site as “minimally manipulated” therapies. Despite
hese advantages, many challenges remain in the development and
ommercialisation of autologous cell-based therapies. It is possible
hat the route of the target disease might be with the patient’s own
ells and it would therefore be better to avoid using them, or indeed
he patient is unable to undergo the procedure required for cell iso-
ation. Furthermore, issues surrounding the quality test burden and
ogistics add to the complexity for the production and delivery of a
ost effective autologous cell-based therapy and failure of product
atches would be likely to lead to an inability to treat patients.
Regenerative cell-based therapies where the donor and the
ecipient are different individuals are termed “allogeneic”. This cre-
tes an off-the-shelf business model, which is far more akin to
urrent biopharmaceuticals, representing an attractive commer-
ial opportunity. Assuming cell products can be stored long-term
.e. their manufacture is decoupled from delivery to the patient; the
ells can be made available on demand. In contrast to autologous
herapies, allogeneic products have the potential to be scaled-up,
otentially beneﬁtting from the economies of scale experienced by
raditional bioprocesses [5,6]. As such, manufacturing technologies
mployed for allogeneic therapies are likely to differ in terms of
ature and scale including the use of traditional scale-up technol-
gy such as stirred-tank bioreactors [7,8]. Allogeneic therapies will
owever create a product that is “more than minimally manipu-
ated”, which means that the regulatory pathway requires far more
ime and resource to complete.
For the development of both autologous and allogeneic cell-
ased therapies, the characterization of the input material from
ifferent donors will be necessary to assess any potential variation
n the manufacturing and delivery process. The aim of this study,
herefore, is to characterize the input material for an hMSC therapy
ioprocess and then assess the implications for the development
nd operation of a large scale “more than minimally manipulated”
ell-based therapy bioprocess.
. Materials and methods
.1. Culture of hMSCs
Bone marrow derived human mesenchymal stem cells (BM-
MSCs) were purchased or donated as mononuclear cells (MNCs)
rom Lonza (USA) after the patient had given informed consent.
he local Ethical Committee approved the use of the sample
or research. MNCs from Lonza were initially plated at a cell
ensity of 100,000 MNCs cm−2 with the ﬁrst medium exchange
aking place on day 2 and every 3 days thereafter. Human
SCs were cryopreserved at passage 0 to passage 2 at a den-
ity of either 1 × 106 cells ml−1 or 2 × 106 cells ml−1 in a freezeneering Journal 108 (2016) 14–23 15
medium containing 90% (v/v) FBS (Hyclone, Belgium) and 10%
(v/v) dimethylsulphoxide (DMSO). Cells suspended in 1 ml  freeze
medium were placed into 2 ml  cryovials and placed in a −80 ◦C
freezer to passively cool at a rate of 1 ◦C min−1. After 24 h, cells
were placed in the vapor phase of a monitored liquid nitrogen
cryostorage bank for long-term storage.
Cells were grown in T-ﬂasks seeded at 5000 cells cm−2 in a
humidiﬁed atmosphere at 37 ◦C in air containing 5% CO2. Cells were
cultured in Dulbecco’s Modiﬁed Eagle Medium (DMEM; Lonza, UK)
supplemented with 10% (v/v) fetal bovine serum (FBS; Hyclone) and
2 mM Ultra-glutamine (Lonza, UK). A complete medium exchange
was performed on day 3 and cells were passaged at day 6 of cul-
ture (established time to conﬂuency). On passage, the BM-hMSCs
were washed with Ca2+ and Mg2+ free phosphate buffered saline
(PBS) (Lonza, UK) and then incubated for 5 min with trypsin (0.25
%)/EDTA solution (Lonza, UK) to aid cell detachment from the cul-
ture surface. Trypsin was then inactivated by the addition of fresh
growth medium equivalent to 3× the volume of the trypsin solution
used for cell detachment. The cell suspension was  then centrifuged
at 220 × g for 5 min  at room temperature, the supernatant discarded
and the remaining pellet re-suspended in an appropriate volume
of culture medium. Viable cells were counted and an appropriate
number of cells were then re-seeded into a fresh tissue culture ﬂask.
2.2. Analytical techniques
Cell counting and viability (via propidium iodide exclusion) was
performed using a NucleoCounter NC-100 automatic mammalian
cell counter (Chemometec, Denmark). To assess the metabolic
activity of the BM-hMSCs during culture, 1 ml  media samples were
taken from each T-75 culture ﬂask, stored initially at −18 ◦C and
transferred to −80 ◦C for permanent storage. Multiple media sam-
ples were thawed, randomised and analysed for glucose (g/L),
lactate (g/L) and ammonium (mmol/L) using the BioProﬁle FLEX
(Nova Biomedical, USA).
2.3. Immunophenotype analysis
Immunophenotype analysis was  performed by multiparameter
ﬂow cytometry before and after hMSC expansion using a previously
developed protocol [9]. Brieﬂy, detached cells were suspended in
growth medium and loaded onto a 96 well plate. The plate was
centrifuged for 5 min  at 220 × g. The aspirate was removed and the
cells re-suspended and washed in ﬂow cytometry staining buffer
(R&D Systems, UK) and the centrifugation cycle repeated. The cells
were stained for 30 min  in the dark at room temperature with
ﬂuorescent monoclonal antibodies against CD34 (PE-CY5), CD73
(PE-Cy7), CD90 (APC), CD105 (PE) and HLA-DR (FITC, all from BD
Biosciences, UK) in addition with the corresponding isotype con-
trols. All data was  obtained using a Guava easyCyte 8HT ﬂow
cytometer (Merck Millipore, UK) equipped with 488 and 640 nm
excitation running guavaSoft Incyte acquisition software (v2.5). A
minimum of 10,000 gated (Forward scatter/Side scatter) events
were recorded for each sample. Post-acquisition analysis and com-
pensation was performed with FlowJo v7.6.5 (Treestar Inc, USA)
software.
2.4. Tri-lineage differentiation potential
The hMSC differentiation was  induced using StemPro Differ-
entiation Medium (Thermo Fisher, UK) as per the manufacturer’s
instructions. After 21 days the differentiation media were removed,
cells rinsed with PBS then ﬁxed with 4% (v/v) PFA at room
temperature. Adipocytes were stained with 1% (w/v) Oil Red O
(Sigma–Aldrich, UK) in isopropanol at room temperature and
rinsed with distilled water. Osteoblasts were incubated with 2.5%
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v/v) silver nitrate (Sigma–Aldrich, UK) under ultraviolet light
30 min  exposure), rinsed with distilled water and stained with
ast violet solution (Sigma–Aldrich, UK) containing 4% (v/v) napthol
S-MX phosphate alkaline (Sigma–Aldrich, UK) for 45 min  at room
emperature in the dark. Chondrocytes were stained with 1%
w/v) Alcian blue (Sigma–Aldrich, UK) in 0.1 M hydrochloric acid
Sigma–Aldrich, UK). After 30 min  incubation, cells were rinsed
hree times with 0.1 M hydrochloric acid (Sigma–Aldrich, UK). After
taining, differentiated cells were visualised under a light micro-
cope (Nikon Eclipse TS-100, UK).
.5. Quantitative osteogenesis assay
Osteogenesis was quantiﬁed by hMSC collagen production using
he Sircol Assay (Biocolour, UK) following osteogenic differentia-
ion. Collagen standards of acid-soluble collagen Type I at 0, 0.1, 0.2
nd 0.4 g L−1 were used to quantify the collagen production. BM-
MSCs were seeded at 10,000 cells cm−2 in a 12 well plate with
he previously described cell culture medium; after 3 days culture
rowth medium was exchanged to PRIME-XV® Osteogenic Differ-
ntiation Serum-Free Medium (SFM) (Irvine Scientiﬁc, USA) and
ultured for 9 days with a medium exchange taking place every 3
ays. To quantify the collagen production cells were ﬁxed with a
olution of 5% acetic acid (v/v) (Sigma, UK) and 9% formaldehyde
v/v) (Sigma, UK) for 30 min  at room temperature. The monolayer
as washed and Sircol Dye Reagent (Biocolour, UK) was added to
ach well for 30 min, removed and the cell monolayer was  washed
ith Acid-Salt Wash Reagent (Biocolour, UK). Alkali Reagent (Bio-
olour, UK) was added to each well to release the collagen-bound
ircol Dye Reagent and the resulting solution along with the colla-
en standard was quantiﬁed on a microplate reader (BMG Labtech,
K) at an absorbance of 555 nm.
.6. Colony-forming unit ﬁbroblast (CFU-f) efﬁciency
To assess the CFU-f efﬁciency, BM-hMSCs were seeded in a T-
ask at 10 cells cm−2 and cultured with a medium exchange every
–5 days. Following 14 days culture, cells were washed with PBS
nd ﬁxed in 4% formaldehyde (v/v) (Sigma, UK) for 30 min. Colonies
ere stained with 1% crystal violet (Sigma, UK) in 100% methanol
w/v) for 30 min. Stained colonies that were made up of more than
5 cells were recorded as CFUs.
.7. IL-6 production assay
Human MSCs were seeded into T-ﬂasks and maintained as
escribed above. On day 3, the medium was removed and the cells
ere washed once with PBS. Fresh medium was added containing
0 ng/ml of recombinant human interferon- (IFN-) and tumour
ecrosis factor-ɑ (TNF-ɑ)  (both from Invitrogen, UK). After 24, 48
r 72 h the medium was harvested and analysed via ELISA. IL-6
oncentration was measured with human IL-6 ELISA Set (BD Bio-
ciences, UK) according to the manufacturer’s instructions. Brieﬂy,
apture IL-6 antibody was coated onto Maxisorp 96-well plates.
amples and standards were loaded on the plates and incubated for
wo hours at room temperature followed by washing with buffer
olution. The wells were then incubated with biotinylated anti-
uman IL-6 antibody and Streptavidin–horseradish peroxidase
onjugate (SAv-HRP). Substrate solution containing tetramethyl-
enzidine (TMB) and hydrogen peroxide was then added to each
ell for 30 min  in the dark. Stop solution was then added to each
ell. Absorbance was read at 450 nm using a FLUOstar Omega plate
eader (BMG Labtech, UK).neering Journal 108 (2016) 14–23
2.8. Kynurenine assay
150 l of medium used for the IL-6 assay was incubated with
50 l of 30% (vol/vol) trichloroacetic acid (Sigma–Alridch, UK) for
10 min  at 50 ◦C, vortexed and centrifuged at 10,000 × g for 5 min.
75 l of the supernatant was  transferred to a 96-well plate fol-
lowed by addition of equal volume of Ehrlich’s reagent (1% w/v
p-dimethylbenzaldehyde in glacial acetic acid) (Sigma–Aldrich, UK)
for 10 min  at room temperature. Optical absorbance was measured
at 492 nm. The amount of kynurenine was determined using a stan-
dard curve from 0 to 100 M.
2.9. Short tandem repeat (STR) analysis
Short tandem repeat analysis was  completed by LGC Standards
(UK) under their cell line authentication program.
CFUfEfﬁciency =
(
Numberofcoloniesformed
Numberofcellsseeded
)
× 100 (1)
SpeciﬁcGrowthRate,  =
ln
(
Cx (t)/Cx (0)
)
t
(2)
Where  = speciﬁc growth rate (h−1), Cx(t) and Cx(0) = cell numbers
at the end and start of exponential growth phase respectively and
t = time (h)
Populationdoubling = 1
log (2)
× log
(
Cx (t)
Cx (0)
)
(3)
Where Cx(t) and Cx(0) = cell numbers at the end and start of expo-
nential growth phase respectively and t = time (h)
Foldincrease = Cx (f )
Cx (0)
(4)
Where Cx(f) = ﬁnal cell number at the end of passage and
Cx(0) = initial cell number
Speciﬁc metaboliteﬂux, qmet = 
Cx (0)
× Cmet (t) − Cmet (0)
et − 1 (5)
Where qmet = speciﬁc metabolite ﬂux,  = speciﬁc growth rate
(day−1), Cmet(t) and Cmet(0) = concentration of metabolite at the
start and end of exponential growth phase respectively, Cx(0) = cell
number at the start of exponential growth phase and t = time (day)
Lactateyieldfromglucose, YLac⁄Gluc =
Lac
Gluc
(6)
Where YLac/Gluc = lactate yield from glucose, Lac = lactate produc-
tion over speciﬁed time period and Gluc = glucose consumption
over same time period.
2.11. Statistical analysis
Results were deemed to be signiﬁcant if p < 0.05 using a two-
tailed Students t-test.
3. Results and discussion
3.1. Autologous biop rocess development
As mentioned previously, autologous cell-based therapy prod-
ucts must be scaled-out to meet demand and the process must have
the capability to deal with innate variation that exists when man-
ufacturing each product batch from a different donor. With this in
mind, the variation in input material should be assessed in order to
inform product and process development, increase efﬁciency and
reduce costs [10]. In line with our previous work aimed at develop-
ing a quantitative approach for hMSC culture, we  expanded upon
this by including multiple hMSC donor cells (Table 1) as well as
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Fig. 1. Growth potential of the ﬁve BM-hMSC lines over ﬁve passages. Showing (A) Cumulative population doublings; (B) variation in cumulative population doublings across
all  six BM-hMSC lines; (C) speciﬁc growth rate; (D) fold Increase. (Data shows mean ± SD, n = 4).
Table 1
Summary of BM-hMSC line nomenclature and donor information.
hMSC line
nomenclature
Donor
age
Donor
gender
Donor
ethnicity
M0  20 Male Black
M1  27 Male Black
M2  19 Female Black
n
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Table 2
Process time required to manufacture a theoretical batch of 350 M hMSCs demon-
strating variation in process time between and within donor material. Assumptions
— starting population of 2 million hMSCs, expanded in the T-ﬂask process presented
here.
Per dose of 350M hMSCs
hMSCs
line
Process
time days
Number of
passages
Inter batch
range (days)
ml culture media
per million cells
M0  14.2 3 0.5 87
M1  23.3 4 5.0 159
M2  17.6 4 1.6 117M3  24 Male Caucasian
M4  25 Female Hispanic
ew analytical techniques [11]. The variation in growth kinetics of
he ﬁve BM-hMSC lines can be seen in Fig. 1A, with 13.74 ± 0.33
umulative population doublings achieved by M0  over 30 days in
ulture, compared to M3  which only achieved 7.81 ± 0.32 over the
ame period of time. The measured variation in growth kinetics
ill likely have implications for hMSC products that require cul-
ure expansion, as a minimum number of cells will be required
o be generated within a set time frame, to meet the speciﬁcation
f the product. With such differences in the growth of BM-hMSCs
etween donors this makes the manufacture of autologous cell-
ased products a real challenge and solutions have been proposed
o alleviate this, such as reducing the expansion of the product
nd utilising functionally closed automated manufacturing devices
12]. The implications of this difference in growth kinetics will also
mpact the logistics and timing, as the process will typically have to
perate at the “worst-case-scenario”. Table 2 shows the variation
n process time for each of these donor hMSC lines for a theoreti-
al process with the batch requirement of 350 million hMSCs [1].
he range in the process time between these donor hMSC lines
or this hypothetical product is over 13 days, creating potential
atch timing issues when manufacturing products from multiple
atients. This also creates differences in the medium utilisation to
chieve each patient dose, for example M1  requires almost double
he volume of medium per million cells compared to M0 (Table 2).
his will likely impact of the overall cost of goods for patient spe-
iﬁc processes, as medium and particularly the serum component
f medium is likely to be a key cost driver during process scale-
ut [13]. Table 2 also shows the inter batch range for each of theseM3  27.4 5 6.8 151
M4  18.7 4 0.9 129
donor hMSC lines, with cells requiring higher processing times gen-
erally showing increased variation. Increased inter batch range has
the potential to reduce productivity as process timing will need to
be ﬂexible enough to accommodate this variation and production
rates are likely to be decreased.
The logistics of isolating cells from the patient, processing these
cells and returning them to the patient will have to take place in
a limited time period, for example, Provenge® (Dendreon Corpo-
ration, USA) a non-expanded cell-based therapy has a processing
time of up to 18 h. Process timings must therefore be clearly deﬁned
which will be challenging when the difference in growth kinetics
is so variable and the process must be run assuming the minimum
possible expansion rate of the product to avoid creating a produc-
tion bottleneck. The implications of this are that low growth rate
cells greatly reduce the efﬁciency of the process, which is likely to
increase the cost of developing autologous cell-based products.
The relative metabolite production rate and nutrient consump-
tion rate can be seen in Fig. 2, with the per cell metabolite ﬂux
showing differences across the ﬁve BM-hMSC lines over the 30 days
in culture. The net glucose consumption rate for the BM-hMSC lines
remained relatively stable throughout the 30 days of culture with
the exception of M3,  which showed an increase at the end of the
culture period. The increase in net glucose consumption of M3 is
linked with an increase in the net lactate production rate (Fig. 2b).
18 T.R.J. Heathman et al. / Biochemical Engineering Journal 108 (2016) 14–23
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ates;  (C) speciﬁc ammonium production rates; (D) speciﬁc yield of lactate from glu
his is primarily associated with a reduction in the proliferative
ate of the M3  cell line towards the end of the culture process. Vari-
tion in net metabolite ﬂux across the cell lines has implications
or the operation and control of autologous bioprocesses, as this
ill change the required nutrient feeding strategy employed during
he manufacturing process. Furthermore, an increase in the lactate
roduction of M3  (Fig. 3) has the potential to cause the build-up of
oxic components that would need to be limited either by dilution
r removal from the process. If the levels of nutrient utilization and
etabolite production vary between donors in this way, control
ystems must be developed and integrated within the manufactur-
ng process with the ability to neutralize this effect and maintain a
onsistent process, which will be critical for the successful regula-
ion of an autologous manufacturing process.
Morphology has been used for decades as a qualitative assess-
ent of hMSC identity and has also been used as part of the release
est for approved cell-based therapies, for example Carticel® (Gen-
yme, USA) includes morphology as part of their wider product
elease tests. Fig. 4 shows the difference between the morphol-
gy of BM-hMSC lines M2  and M3  after ﬁve days in culture, with
lear differences between them. The implications for this differ-
nce in cell morphology can be appreciated when considering that
n adherent cell manufacturing process will be based upon a ﬁxed
urface area for cell expansion. With such differences in cell mor-
hology in terms of size and alignment, the effective number of cells
er square centimeter of these two cell lines when conﬂuent varies
reatly, creating an issue for these manufacturing processes based
pon a ﬁxed surface area. In these processes, the ﬁnal cell number
t harvest will vary greatly between patients due to these morpho-
ogical differences. Considering that manufacturing processes for
utologous cell-based therapies will likely have a minimum num-
er of cells per dose, this variation will greatly increase the risk of
uffering product batch failure as this minimum number of cells
er dose may  not be met. Increased batch failure rate will likely
ncrease the inherent risk and inevitably the cost of autologous
ell-based therapy products. In addition to the challenges relat-
ng to the number of cells obtainable per unit area, the cell size
ill likely play a role in the downstream processing and delivery
f the cells to the patient [8]. The isolation procedure and subse-
uent positive selection of input material for these patient speciﬁcges. Showing (A) Speciﬁc glucose consumption rates; (B) speciﬁc lactate production
 (Data shows mean ± SD, n = 4).
processes will be critical in reducing the failure rate of these man-
ufacturing processes. Robust and reproducible isolation protocols
need to be established to minimize variability of source material
and selection criteria based on desired product attributes should
be identiﬁed at an early stage of development. These isolation and
selection processes will likely reduce process variation by placing
controls on the input to the process, which will be critical to the
success of these personalized cell-based therapies.
As well as the cost implications of a product batch failure it is
also important to consider the implications of such an occurrence in
terms of not being able to treat a patient with an autologous therapy
[14]. This represents a limitation to the use of such therapies and
creates a challenge that has not been experienced with traditional
medical treatments. Depending on the severity of the clinical indi-
cation, this has the potential to cause complications and repetition
of the isolation, expansion and delivery process may  not be possi-
ble. It is clear that autologous therapies represent an opportunity
to deliver cell-based therapies from a scale-out process and require
innovation beyond current biopharmaceutical manufacture, how-
ever, subtle differences in this approach as highlighted above must
be considered during product development and commercialization.
3.2. Allogeneic bioprocess development
As described above, the development of allogeneic cell-based
therapies represents an off-the-shelf business model more akin to
current biopharmaceutical production. These allogeneic processes
can be scaled-up to treat multiple patients from a single batch
which is likely to increase the cost-effectiveness of the product due
to increasing economies of scale, simpler supply logistics and larger
amounts of material for quality control (QC)/quality assurance (QA)
testing in comparison to autologous processes. Material from mul-
tiple donors must therefore be assessed in order to create a master
cell bank with enough material to manufacture cells to meet the
commercial demand for the cell-based therapy.
Fig. 1b shows the box and whisker plots for the variation across
ﬁve BM-hMSC lines, which increases with passage number and time
in culture. The divergence in cell growth will create an issue for
processes with a high expansion ratio, as a consistent process will
be harder to obtain the longer the cells are in culture. This high-
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Fig. 3. Metabolite consumption and production showing the difference between the M2  and M3 BM-hMSC lines over ﬁve passages. Daily media samples were taken and
analysed for glucose, lactate and ammonium concentration. (Data shows mean ± SD, n = 4).
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pFig. 4. Phase contrast image showing the difference in BM-hM
ights the importance of developing a process control strategy that
s capable of reducing this divergent culture, minimizing the time
equired for in vitro expansion, or ideally producing a convergent
rocess, once it is transferred to a large-scale bioreactor system.
s well as process parameters such as dissolved oxygen concen-
ration and pH, this control system must be able to maintain a
table level of nutrients and metabolites, which will be different
or each cell line, as identiﬁed in Fig. 3. Control of nutrients and
etabolites will become particularly important if the bioreactor
rocess is operated at high cell densities, as the consumption ofay six morphology between the M2 (A) and M3  (B) cell lines.
nutrients and production of metabolites will occur at an increasing
rate. The divergence in growth characteristics of BM-hMSCs from
multiple donors has implications for the development of allogeneic
cell-based therapy manufacturing processes, as they will require a
high cell expansion ratio at large scale in order to produce suf-
ﬁcient cell numbers to meet the product demand. Furthermore,
as the cells are cultured for a longer period of time, the number
of manipulations increases, which has the potential to introduce
increased variability into the process. Automated and closed pro-
cesses have the potential to reduce the inherent variability in each
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Table  3
Multiparameter ﬂow cytometry showing percentage co-expression of CD90+,
CD73+, CD105+, CD34- & HLA-DR- of each BM-hMSC line at 0 h (passage 1) and
after 720 h (passage 5). Mean value ± SD, in all cases 10,000 events were measured.
hMSC
line
Day 0 (P3)
culture
Day 30 (Pg)
culture
M0 98.97 ± 0.19% 97.78 ± 2.26%
M1  96.21 ± 0.22% 95.97 ± 0.42%
M2  98.19 ± 0.09% 95.13 ± 2.53%
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nM3  93.60 ± 2.51% 96.56 ± 0.42%
M4  98.14 ± 0.94% 93.17 ± 1.60%
f these process manipulations and are likely to play a key role in
he development of allogeneic cell-based therapies.
The development of an allogeneic product also necessitates a
aster cell bank, from which the ﬁnal product can be manufactured
15]. The cost of developing a master cell bank is typically high and
annot be recovered until the product receives market approval,
dding to the funding gap in development of allogeneic cell-based
herapies. The quality and consistency of the master bank is critical,
s once it has been created it cannot be changed and therefore a high
evel of product and process understanding is required, coupled
ith rigorous safety and quality testing to ensure that the product
n the master cell bank is suitable for the manufacture of the cell-
ased therapy product.
.3. Product characterization
Perhaps one of most important aspects of the manufacture of
ell-based therapy products is the deﬁnition and measurement of
ell characteristics [16]. These can be broken down into identity,
otency, purity and safety which must all be considered during
roduct development [17]. Despite the differences in cell growth
nd net metabolite ﬂux described in Sections 3.1 and 3.2, all of
he BM-hMSC lines displayed the expected immunophenotype
y the positive co-expression of CD73, 90 and 105 and negative
o-expression of CD34 and HLA-DR at the start and end of the
ulture process (Table 3). This is combined with the demonstra-
ion of BM-hMSC tri-lineage differentiation potential, an example
f this is shown for M2  and M3  cell lines in Fig. 5, demonstrating
hat the BM-hMSC lines meet the minimum criteria as deﬁned by
he International Society of Cellular Therapy (ISCT) [18], despite
he differences discussed in Sections 3.1 and 3.2. Short tandem
epeat (STR) analysis of these BM-hMSC lines shows that they have
etained the 16 key loci they are expected to express, indicating that
ig. 5. Tri-lineage differentiation potential of two BM-hMSC lines using phase-contrast m
nd  calcium deposition, adipogenic differentiation by staining with Oil Red O and chond
 = 4.neering Journal 108 (2016) 14–23
all of the cell lines have retained the characteristic genotype of BM-
hMSCs throughout the entire culture process (see Supplementary
material).
It is widely acknowledged that a better understanding of the
mechanism by which BM-hMSCs elicit their therapeutic action will
be required before processes can be developed in order to preserve
or potentially maximize it. Fig. 6a shows the colony forming efﬁ-
ciency of three of the BM-hMSC lines, M2,  M3  and M4.  Despite
similarities in growth kinetics between M2  and M4  their ability to
form colonies over ten passages in culture is very different, which
would pose a challenge if the products were being assessed under
the same QA guidelines. If the product does not meet the QA spec-
iﬁcation deﬁned during clinical development, the product batch
will be failed, creating signiﬁcant consequences for both autologous
and allogeneic processes. As allogeneic manufacturing processes
are operated at larger batch sizes, the failure to meet the product
release criteria will result in the loss of a large amount of invested
capital, increasing the ﬁnancial risk in the process. In contrast,
the implications of a product batch failure during an autologous
cell-based therapy process are that the patient will go untreated.
Depending on the severity of the clinical indication targeted, this
has the potential to be fatal, which will have severe implications
for the health of the patient.
The osteogenic potential of M2,  M3  and M4  has also been quan-
tiﬁed using collagen production under nine days of osteogenic
differentiation (Fig. 6b). As with the colony forming unit ﬁbroblast
efﬁciency, the relative production of collagen under osteogenic
conditions reduced signiﬁcantly for M3 and M4  from passage three
to passage ten, whilst the collagen production from the M2  cell
line remained lower throughout culture. The loss in hMSC multi-
potency during in vitro expansion has previously been related to a
loss of in vivo bone formation [19], which could be used as a critical-
to-quality attribute (CQA) for a clinical indication relating to bone
tissue regeneration. Considering the rapid loss in activity after pas-
sage three, this would potentially limit the use of culture expanded
BM-hMSCs for this type of clinical indication.
Aside from these more traditional clinical indications for BM-
hMSCs based on differentiation, there has been growing clinical
evidence to suggest that part of their putative mechanism of action
lies within their ability for immune modulation, suppressing tis-
sue rejection by inhibiting the response of the patient’s lymphatic
cells [20,21]. The response of the M2,  M3 and M4 cell lines to a pro-
inﬂammatory environment has been assessed by the production
of interleukin 6 (IL-6) and kynurenine throughout the culture pro-
cess. IL-6 has been previously reported to inhibit differentiation
icroscopy. Showing osteogenic differentiation by staining for alkaline phosphatase
rogenic differentiation by staining with Alcian Blue. Images are representative of
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Fig. 6. Further characterization of three of the BM-hMSC lines throughout culture showing the differences in the colony forming unit ﬁbroblast efﬁciency (A) and quantiﬁcation
of  the collagen deposition after nine days under osteogenic conditions (B). (Data shows mean ± SD, n = 4).
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cig. 7. Immunomodulatory characterization of three of the BM-hMSC lines throug
roduction of kynurenine over three days (B) in response to inﬂammatory stimuli
ouble letter (p < 0.01) between donors. A – Day 0, B – Day 12, C – Day 24.
f dendritic cells and thus the activation of T-lymphocytes [22].
ig. 7a shows the concentration of IL-6 over 72 h at passage 3, 5 and
 when the BM-hMSCs were cultured with inﬂammatory stimuli.
4 secreted the most IL-6 through passage 3–5 (p < 0.01) with the
aximum level of 80.8 ng/ml ± 8.4 whereas M3  produced a maxi-
um  concentration of 36.3 ng/ml ± 3.65. The rate of response for
4 was also quicker when compared to M2  and M3  as there was
reater secretion of IL-6 within the ﬁrst 24 and 48 h.
Kynurenine, a measure of tryptophan metabolism by
ndoleamine 2,3-dioxygenase (IDO), was also measured over
he same period. IDO activity in BM-hMSCs has been shown to
nhibit allogeneic T cell responses in mixed lymphocyte reactions
23]. In contrast to IL-6, M2  was found to produce the most kynure-
ine over each passage (Fig. 7b). The rate of kynurenine production
an also be seen over the ﬁrst 48 h, in all cell lines the rate ofculture showing the differences in expression of IL-6 over three days (A) and the
a shows mean ± SD, n = 4). Statistical analysis shows single letter (no signiﬁcance)
response is reduced over the extended passage again suggesting
a limit of culture-expanded BM-hMSCs for immunotherapy.
Furthermore, as BM-hMSCs may  only have a limited in vivo
lifetime a faster response to the environment will be beneﬁcial.
Due to the putative multifaceted immunomodulatory mechanism
of BM-hMSCs the critical mechanism of action (MoA) must be
determined to then develop a robust and reproducible assay that
can be used to screen input donor material. Whatever the MoA  of
BM-hMSCs for a speciﬁc clinical indication, it will be important
to maintain consistency in these key attributes, demonstrating
product understanding by maintaining a state of control over the
product throughout the manufacturing process.
It has been shown previously that donor age and gender has an
effect on the function of BM-hMSCs [24], particularly relating to
their ability for immunoregulation in vivo [25]. With these intrin-
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ic donor characteristics having such an effect on the functionality
f the cell-based therapy products, it is important to understand
ow they will affect the ﬁnal product. To maintain the consis-
ency required within the process, it will likely be necessary to
re-screen donor material for both autologous and allogeneic prod-
cts prior to the expansion process. By taking this approach it might
e possible to reduce the impact of the variability in donor BM-
MSCs described, however, the ethical implication of pre-selecting
atients for autologous cell-based therapies must be carefully con-
idered.
.4. Demonstrating comparability
Any changes to the manufacturing process during clinical devel-
pment will require validation of the process to ensure it remains
omparable before and after the change. Validating process changes
ill require signiﬁcant time and resource, as well as the develop-
ent of functional assays to demonstrate that there has been no
hange to the safety or function of the cell-based therapy product.
n addition to making process changes, comparability must also be
emonstrated if a cell-based therapy product is to be manufactured
t multiple facilities [12]. Multisite manufacture has the advantage
f reducing the capital cost for scaling out product manufacture to
eet commercial demand as well as reducing the inherent risk of
aving a single manufacturing facility.
The process of demonstrating product comparability is not a
rivial one and must go beyond the conventional in-process and
roduct release characterization, requiring a large amount of pro-
ess and product data during development to act as a stable
oundation from which to demonstrate product comparability. At
he core of this dataset is the establishment of a set of product
QAs linked to the product mechanism of action for a speciﬁc clini-
al indication. Demonstrating this level of product comparability
or a process that is expanding cells from multiple donors will
e challenging, as variability in the input material will reduce the
rocess consistency. In addition to this, with a divergence in BM-
MSC growth as seen in Fig. 1b, increasing the number of product
opulation doublings will make the process of demonstrating com-
arability more challenging still. Driving a consistent process will
herefore be a logical ﬁrst step towards developing these compa-
able processes, with reliable control strategies forming the basis
or this consistency. Another aspect of ensuring consistency is suf-
cient control on the process input materials such as reagents,
ulture medium and disposables.
As can be seen from Figs. 6 and 7, the characteristics of each of
hese cell lines changes throughout the culture process. Depend-
ng on the target indication and the set of CQAs for the cell-based
herapy product, this will make the demonstration of process com-
arability challenging for expanded cell-based therapy products.
ach of the product characteristics monitored during this study
ave shown a reduction as the number of cell population dou-
lings increases, a clear sign that reducing the expansion ratio of the
roduct where possible will improve the chances of maintaining
roduct functionality and demonstrating comparability. Under-
tanding these process changes could be greatly improved by a
etailed analysis of the metabolic activity of these products. Fig. 2
hows the net metabolite ﬂux of glucose, lactate and ammonium,
owever, understanding the metabolic intermediates such as pyru-
ate would also aid in demonstrating that process changes have
ot inadvertently affected the product characteristics, an important
spect of process comparability..5. Process analytical technology (PAT)
As highlighted above, deﬁning and measuring relevant product
haracteristics forms a critical part of developing successful manu-neering Journal 108 (2016) 14–23
facturing processes for cell-based therapies. If these processes are
to be successfully transferred to a scalable manufacturing plat-
form, these parameters must not only be measured, but must be
integrated into online monitoring and control strategies. Process
analytical technology or PAT is a system for analyzing and con-
trolling manufacturing processes through measurement of product
attributes to ensure ﬁnal product quality, proposed by the Food and
Drug Administration (FDA) [26].
This process can be broken down into three distinctive steps
[27]:
1. Understanding of the product quality attributes and how process
parameters affect them.
2. Ability to analyze quality attributes and monitor critical process
parameters.
3. Control of the critical process parameters to achieve consistent
product quality.
It will therefore be desirable to begin to measure online parame-
ters in order to develop control systems to ensure that the product
characteristics described in section 3.3 remain consistent. These
relevant process parameters are likely to include a combination of
cell growth, medium temperature, pH, pO2 and pCO2, which are
commonplace in current biopharmaceutical production processes
[28]. In addition to this, process parameters such as metabolite con-
centrations (glucose, lactate, ammonia and glutamine) can play a
role in product understanding during the manufacturing process
and should be controlled to ensure consistent product quality. The
beneﬁt of operating a production process under the guidance of PAT
will likely be a reduction in product variability, which will reduce
the likelihood of product batch failure. Having a detailed product
understanding using online measurements also introduces the pos-
sibility for real-time release testing of product batches, which will
reduce costs by reducing the quality test burden at the end of the
process.
4. Conclusions
Characterizing input material from different BM-hMSC donors
has allowed for an assessment of the effect of variation on devel-
oping cell-based therapy manufacturing processes. Identifying the
divergent nature of the growth of multiple BM-hMSC donor lines
has been identiﬁed as a potential issue for the development of
both autologous and allogeneic processes where cell expansion
is required. Furthermore, measuring multiple quality characteris-
tics of these BM-hMSC lines throughout culture has demonstrated
a reduction in quality as the population doubling level increases,
which must be considered as these processes are scaled.
Developing manufacturing processes from multiple BM-hMSC
donors will require an understanding of the effect of donor charac-
teristics on expanded autologous and allogeneic cell-based therapy
bioprocesses. Measuring informative product attributes that are
characteristic of the desired therapeutic effect for each clinical indi-
cation will facilitate the development of consistent manufacturing
processes and will play a key role in unlocking the value of demon-
strating process comparability, allowing for any necessary process
changes and multisite manufacturing models.
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